Cargando…
Gene expression profiling unveils the temporal dynamics of CIGB-300-regulated transcriptome in AML cell lines
BACKGROUND: Protein kinase CK2 activity is implicated in the pathogenesis of various hematological malignancies like Acute Myeloid Leukemia (AML) that remains challenging concerning treatment. This kinase has emerged as an attractive molecular target in therapeutic. Antitumoral peptide CIGB-300 bloc...
Autores principales: | Vázquez-Blomquist, Dania, Ramón, Ailyn C., Rosales, Mauro, Pérez, George V., Rosales, Ailenis, Palenzuela, Daniel, Perera, Yasser, Perea, Silvio E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318747/ https://www.ncbi.nlm.nih.gov/pubmed/37400761 http://dx.doi.org/10.1186/s12864-023-09472-5 |
Ejemplares similares
-
Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300
por: Rosales, Mauro, et al.
Publicado: (2021) -
CIGB-300-Regulated Proteome Reveals Common and Tailored Response Patterns of AML Cells to CK2 Inhibition
por: Rosales, Mauro, et al.
Publicado: (2022) -
CIGB-300 Anticancer Peptide Differentially Interacts with CK2 Subunits and Regulates Specific Signaling Mediators in a Highly Sensitive Large Cell Lung Carcinoma Cell Model
por: Pérez, George V., et al.
Publicado: (2022) -
CIGB-300 Peptide Targets the CK2 Phospho-Acceptor Domain on Human Papillomavirus E7 and Disrupts the Retinoblastoma (RB) Complex in Cervical Cancer Cells
por: Ramón, Ailyn C., et al.
Publicado: (2022) -
Preclinical efficacy of CIGB-300, an anti-CK2 peptide, on breast cancer metastasic colonization
por: Gottardo, Maria F., et al.
Publicado: (2020)